Lipocine annual operating margin
2012
2018
2019
2021
2022
2024
2025
Lipocine's operating margin was −524.69% for fiscal 2025.
View full Lipocine company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −524.69% | −514.37 pp |
| 2024 | 2024-12-31 | −10.31% | +2413.56 pp |
| 2022 | 2022-12-31 | −2,423.88% | −2443.36 pp |
| 2021 | 2021-12-31 | 19.49% | +7838.32 pp |
| 2019 | 2019-12-31 | −7,818.83% | −5172.80 pp |
| 2018 | 2018-12-31 | −2,646.03% | −2696.32 pp |
| 2012 | 2012-12-31 | 50.29% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,495.14% | −1109.11 pp |
| Q1 2026 | 2026-03-31 | −3,224.09% | −997.27 pp |
| Q4 2025 | 2025-12-31 | −219.65% | −265.08 pp |
| Q3 2025 | 2025-09-30 | −2,933.51% | +3.47 pp |
| Q2 2025 | 2025-06-30 | −386.03% | +3290.15 pp |
| Q1 2025 | 2025-03-31 | −2,226.82% | −2269.13 pp |
| Q4 2024 | 2024-12-31 | 45.43% | +1245.01 pp |
| Q3 2024 | 2024-09-30 | −2,936.98% | +4952.88 pp |
| Q2 2024 | 2024-06-30 | −3,676.18% | −2970.67 pp |
| Q1 2024 | 2024-03-31 | 42.31% | +6467.87 pp |
| Q4 2023 | 2023-12-31 | −1,199.58% | +603.97 pp |
| Q1 2023 | 2023-03-31 | −7,889.86% | −7273.78 pp |
| Q2 2022 | 2022-06-30 | −705.51% | — |
| Q3 2021 | 2021-09-30 | −6,425.56% | — |
| Q3 2019 | 2019-09-30 | −1,803.56% | — |
| Q1 2018 | 2018-03-31 | −616.07% | — |
Over the last five reported fiscal years, Lipocine's operating margin increased from −2,646.03% to −524.69%, a change of +2121.34 percentage points. The latest reported quarter, Q2 2026, shows −1,495.14%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lipocine filings at SEC.gov ↗